Literature DB >> 15013438

Human cytomegalovirus UL18 alleviated human NK-mediated swine endothelial cell lysis.

Jung-Sik Kim1, Seung-Eun Choi, Il-Hee Yun, Jae-Young Kim, Curie Ahn, Sang-Joon Kim, Jongwon Ha, Eung-Soo Hwang, Chang-Yong Cha, Shuji Miyagawa, Chung-Gyu Park.   

Abstract

Human cytomegalovirus UL18, a MHC class I homologue, is known to serve as a natural killer cell (NK) decoy and to ligate NK inhibitory receptors to prevent lysis of an infected target cell. To explore whether the cell surface expression of UL18 represents a potential immune suppressive approach to evade NK-mediated cytotoxicity in the prevention of xenograft rejection, we examined the effect of the UL18 expression in vitro upon human NK-mediated cytotoxicity against swine endothelial cells (SECs). UL18 expression on SECs by a retroviral vector (PLNCX2) significantly suppressed NK-mediated SEC lysis by approximately 25-100%. The protective effect of UL18 could be mediated through ILT-2 inhibitory receptor on NKs. Additionally, the interaction between UL18 and NKs resulted in the significant reduction of IFN-gamma production. This study demonstrates that UL18 can serve as an effective tool for the evasion of NK-mediated cytotoxicity and for the inhibition of IFN-gamma production during xenograft rejection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15013438     DOI: 10.1016/j.bbrc.2004.01.027

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Herpesvirus Evasion of Natural Killer Cells.

Authors:  Steffi De Pelsmaeker; Nicolas Romero; Massimo Vitale; Herman W Favoreel
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

Review 2.  Modulation of natural killer cells by human cytomegalovirus.

Authors:  Gavin W G Wilkinson; Peter Tomasec; Richard J Stanton; Melanie Armstrong; Virginie Prod'homme; Rebecca Aicheler; Brian P McSharry; Carole R Rickards; Daniel Cochrane; Sian Llewellyn-Lacey; Eddie C Y Wang; Cora A Griffin; Andrew J Davison
Journal:  J Clin Virol       Date:  2008-03       Impact factor: 3.168

3.  Genetic variability of the major histocompatibility complex class I homologue encoded by human cytomegalovirus leads to differential binding to the inhibitory receptor ILT2.

Authors:  Mar Valés-Gómez; Mitsunori Shiroishi; Katsumi Maenaka; Hugh T Reyburn
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  Feeling manipulated: cytomegalovirus immune manipulation.

Authors:  Mindy Miller-Kittrell; Tim E Sparer
Journal:  Virol J       Date:  2009-01-09       Impact factor: 4.099

5.  S100A9 protein is a novel ligand for the CD85j receptor and its interaction is implicated in the control of HIV-1 replication by NK cells.

Authors:  Vincent Arnold; Jean-Saville Cummings; Uriel Y Moreno-Nieves; Céline Didier; Adrien Gilbert; Françoise Barré-Sinoussi; Daniel Scott-Algara
Journal:  Retrovirology       Date:  2013-10-24       Impact factor: 4.602

6.  Pseudorabies Virus Infection Causes Downregulation of Ligands for the Activating NK Cell Receptor NKG2D.

Authors:  Sofie Denaeghel; Steffi De Pelsmaeker; Cliff Van Waesberghe; Herman W Favoreel
Journal:  Viruses       Date:  2021-02-09       Impact factor: 5.048

7.  The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1- NK cells.

Authors:  Virginie Prod'homme; Cora Griffin; Rebecca J Aicheler; Eddie C Y Wang; Brian P McSharry; Carole R Rickards; Richard J Stanton; Leszek K Borysiewicz; Miguel López-Botet; Gavin W G Wilkinson; Peter Tomasec
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

8.  Characterization of a highly glycosylated form of the human cytomegalovirus HLA class I homologue gpUL18.

Authors:  Cora Griffin; Eddie C Y Wang; Brian P McSharry; Carole Rickards; Helena Browne; Gavin W G Wilkinson; Peter Tomasec
Journal:  J Gen Virol       Date:  2005-11       Impact factor: 3.891

Review 9.  The Role of NK Cells in Pig-to-Human Xenotransplantation.

Authors:  Gisella Puga Yung; Mårten K J Schneider; Jörg D Seebach
Journal:  J Immunol Res       Date:  2017-12-19       Impact factor: 4.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.